References
- Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302.
- Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020;100(3):adv00032.
- Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
- Atalay S, van den Reek J, den Broeder AA, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2020;156(4):393–400.
- Atalay S, van den Reek J, Otero ME, et al. Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol. 2020;100(19):adv00340.